Cortechs.ai | New Product from Cortechs.ai: PETQuant for Research Use

New Product from Cortechs.ai: PETQuant for Research Use

PQ_head_reversed-01.pngOn March 9, 2016, Cortechs.ai launched a new research product: PETQuant™. PETQuant provides automated and fast post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space, and is compatible with metabolic (FDG) and amyloid-based (florbetapir) tracers.

PETQuant expands the use of NeuroQuant®’s proven and trusted segmentation technology by offering an additional research tool in the evaluation of neurodegenerative dementias, such as Alzheimer’s disease and frontotemporal dementia.

Fast, Accurate and Simplified Quantitative Phenotyping
PETQuant enables clinical researchers to perform post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space

Powered by NeuroQuant
PET tracer bindings are accurately localized to brain structures identified by NeuroQuant 3D T1 MRI segmentation

Completely Automatic
PETQuant offers fully automated and consistent results

Fast and Reliable Quantitative Data
In about 10 minutes, PETQuant returns a complete report with color overlay and quantitative information for 46 brain structures, for both left and right hemispheres

Amyloid Deposition and Metabolism Analysis
PETQuant provides two separate reports that correspond to the PET tracer used; choose between metabolic (FDG) and amyloid-based (florbetapir) analysis reports

Simplified and Easy-to-Read
Color-coded graphical presentation simplifies quantitative reads

Available Anytime, Anywhere
Secure, cloud-based system provides access anytime, from virtually anywhere

This version of PETQuant is for research purposes only.

For more information on PETQuant or to schedule a demo, visit cortechs.ai/petquant or contact us.

More Resources

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?

07/08/2025

Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroAlign CT

Time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes.

07/07/2025

When to repeat an MRI scan for NeuroQuant®

NeuroQuant® can process an array of exams. However, there are some circumstances that will require you to repeat a scan.
Scroll to Top